Failure to detect differences in proliferation status of nevi from CDKN2A mutation carriers and non-carriers

Journal of Investigative Dermatology

Volumn 118, Issue 2, 2002, Pages 386-387

  Florell, Scott R ^a   Boucher, Kenneth M ^a   Holden, Joseph A ^a   Meyer, Laurence J ^a   Samlowski, Wolfram E ^a   Cannon Albright, Lisa A ^a   Zone, John J ^a   Leachman, Sancy A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR A; DNA TOPOISOMERASE (ATP HYDROLYSING); UNCLASSIFIED DRUG;

CELL CYCLE; CELL PROLIFERATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HETEROZYGOTE DETECTION; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 0036178706     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2002.01659.x     Document Type: Letter

References (22)

1. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p 22
2. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM)
3. Expression and targeting of the apoptosis inhibitor, surviving, in human melanoma
4. DNA topoisomerase II-alpha as a marker of cell proliferation in endocrine and other neoplasms
5. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: An adjunct for recognition of the vertical growth phase in malignant melanomas?
6. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
7. Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma
8. Number, size, and histopathology of nevi in Utah kindreds
9. Ki67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions
10. Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma
11. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations
12. A hypothesis incorporating the histologic characteristics of dysplastic nevi into the normal biological development of melanocytic nevi
13. Melanoma genetics. An update with focus on the CDKN2A (p16)/ARF tumor suppressors
14. DNA topoisomerase II-alpha expression in duct hyperplasia and in situ duct carcinoma of the breast: Correlation with histologic classification of in situ duct carcinoma
15. The p16INK4a/CDKN2A tumor suppressor and its relatives
16. Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions
17. WAF1/Cip1 reflecting proliferation and repair activity in UV-irradiated melanocytic nevi
18. Identification of NF1 mutations in both alleles of a dermal neurofibroma
19. The INK4a/ARF network in tumor suppression
20. Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody: A quantitative immunohistochemical study
21. Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions
22. Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate